Laboratory of Adjuvant and Antigen Research, US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Expert Rev Vaccines. 2012 Jun;11(6):733-44. doi: 10.1586/erv.12.35.
Liposomes containing monophosphoryl lipid A (MPLA) have previously exhibited considerable potency and safety in human trials with a variety of candidate vaccines, including vaccines to malaria, HIV-1 and several different types of cancer. The long history of research and development of MPLA and liposomal MPLA as vaccine adjuvants reveals that there are numerous opportunities for creation and development of generic (nonproprietary) adjuvant system formulations with these materials that are not only highly potent and safe, but also readily available as native materials or as synthetic compounds. They are easily manufactured as potentially inexpensive and easy to use adjuvant systems and might be effective even with synthetic peptides as antigens.
含有单磷酰脂质 A（MPLA）的脂质体在多种候选疫苗的人体试验中表现出相当大的效力和安全性，这些候选疫苗包括疟疾疫苗、HIV-1 疫苗和几种不同类型的癌症疫苗。MPLA 和脂质体 MPLA 作为疫苗佐剂的长期研发历史表明，有许多机会可以用这些材料创造和开发通用（非专利）佐剂系统配方，这些配方不仅效力高且安全，而且还可以作为天然材料或合成化合物随时获得。它们很容易制成潜在廉价且易于使用的佐剂系统，即使使用合成肽作为抗原，也可能有效。
